SARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant

Reference:
Size

10ug, 100ug

Brand

Product type

Host Species

Description of SARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant

General information on SARS-CoV-2 RBD of Spike protein, K417N, L452R, T478K – AY.1/AY.2 lineage – Indian Delta plus variant

The Delta Plus variant was first identified after routine scanning of genomic variations in the lineage B.1.617.2 (original Delta variant) first reported in India. This new variant, which corresponds to lineages AY.1 and AY.2 (the first more abundant than the second), was shown to carry mutation K417N on its receptor-binding domain (RBD) in addition to mutations L452R and T478K previously reported on the original Delta variant.
The K417N amino acid substitution was previously reported in the Beta variant or lineage B.1.351 first identified in South Africa. This change occurs close to a domain targeted by neutralizing antibodies, for this reason, experts believe it might contribute to an enhanced immune evasion in SARS-CoV-2. This may have a synergistic effect in conjugation with mutation L452R, another substitution that is known to contribute to immune evasion in SARS-CoV-2. In contrast, the T478K mutation occurs within the interface between the RBD and the human receptor ACE2. Several reports indicate that the global prevalence of this amino acid change is slowly increasing hinting at its higher transmissibility and perhaps greater affinity towards the human receptor.
The prevalence of lineage AY.1/AY.2 has been steadily increasing in several European countries including the UK, Switzerland, Portugal, and France, and the United States. More recently, Asian countries including India have reported the first cases of the new Delta plus variant. Although previous reports of the Delta have indicated this variant to be more transmissible and likelier to cause a surge in hospitalizations, it remains to be seen if variant Delta plus will cause similar effects. Given the additional immune-escape-conferring mutation, lineage AY.1 might have a slightly better fitness advantage in comparison to the Delta variant. However, more studies are necessary to understand the concerted effect of the three mutations into SARS-CoV-2 transmissibility, virulence, and ability to evade the immune response generated by different COVID-19 vaccines.

Product nameSARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /Synonymslineage AY.1, lineage AY.2, Delta with K417N, B.1.617.2.1, Indian variant, Delta plus variant
ReferencePX-COV-P062
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

Reviews

There are no reviews yet.

Be the first to review “SARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant”

Your email address will not be published. Required fields are marked *

Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: